Portfolio Diversification
Investing can be a satisfying journey yet full of risks. The markets may turn out unpredictable, and individual assets can suffer sharp declines for any number of reasons—such as an economic downturn, geopolitical event, or something specific to the company involved. To get around such uncertainty, you need a solid strategy, and that is where portfolio diversification comes into play. This article deals with the basics, the benefits, and the strategies behind portfolio diversification.
Table of Contents
What is Portfolio Diversification?
Portfolio diversification is an investment strategy in which investments are spread over different classes of assets, sectors, and geographic locations. Its primary objective is to minimise risk by avoiding the risk of overreliance on a single asset or a particular market segment.
For instance, you could invest in several stocks, bonds, and other assets rather than all your money in one stock. If one investment is not good, the others might be okay and balance the loss.
Diversification is “not putting all your eggs in one basket.” It is one key tool for building a resilient investment portfolio.
Understanding Portfolio Diversification
Key Principles
Diversification works based on several principles:
- Asset Allocation: Distribution of the investment amount into different types of assets such as,
- Stocks: Equities are part ownership in the companies
- Bonds: Investments generating periodic interest flow
- Real Estate: Direct property investment or investment trust (REIT).
- Commodities: Invests in commodities like bullion of gold, oil, or agriculture-based products.
- Cash Equivalents: Those are high-liquidity products or money market funds.
- Risk Diversification: Diversifying reduces unsystematic risk. Unsystematic risk, by definition, is a firm-specific or industry-specific risk. Therefore, if the tech industry experiences a downturn, you might not be affected by your investments in healthcare or energy, among others.
- Correlation Management: Diversification is most effective when invested in assets that do not move in the same direction. For instance, stocks and bonds are less correlated, which means they may react differently under the same market conditions.
Strategic Approach
A diversified portfolio is a combination of investments that are aimed at balancing risk and reward. Here are some ways to achieve effective diversification:
- Geographic Diversification: Invest in both domestic and international markets.
- Sector Diversification: Spread investments across industries like technology, healthcare, finance, and energy.
- Market Capitalisation Diversification: Include small-cap, mid-cap, and large-cap companies.
- Investment Style Diversification: Balance growth-oriented and value-oriented investments.
Risk Management in Portfolio Diversification
Risk management is the core of portfolio diversification, which helps reduce losses and protect investors from volatile market movements. Diversification reduces unsystematic risk, which is risk specific to a company or industry, by arranging investments across a range of assets, sectors, and regions.
Importance of Risk Management
Risk is a part of investing, but diversification can reduce it significantly.
- Avoiding Over: Exposure to Single Assets: When you invest in several assets, the poor performance of one does not affect your portfolio much.
- Volatility Reduction: Diversification smooths out returns over time, making your portfolio less likely to experience dramatic fluctuations.
- Hedging against Market Uncertainty: A diversified portfolio can more effectively withstand the effects of recessions or market shocks.
Ways of Diversification
- General Asset Distribution:
You invest in a diversified portfolio of assets, including equities, bonds, real estate, and commodities, so that poor performance in one asset class will not negatively impact the portfolio.
For example, bonds are likely to perform well during an economic downturn. This way, any potential losses in equities would be offset. Diversify your investments in multiple asset classes. For example:
- 60% in equities
- 30% in bonds
- 10% in real estate
- Industry and Geographical Diversification: The investment in various industries and across different countries reduces the likelihood of sector-specific or region-specific risk. Thus, a diversified portfolio may comprise some tech stocks in the United States and healthcare stocks in Singapore to balance risks, both regionally and through industries.
- Mixing Growth with Stability: Including high-risk, high-potential investments like equities and stable, relatively low-risk assets such as government bonds ensures portfolio stability over time.
- Rebalancing: Periodical portfolio adjustment helps achieve or maintain the desired level of risk and asset allocation.
Benefits of Portfolio Diversification
Portfolio diversification offers numerous benefits beyond risk management. Here is a list of some of the benefits:
- Reduced Volatility: Diversification can make a portfolio less choppy and irregular. While in decline in some investments, they could be performing wonderfully on others, producing smooth returns. At worst, in a situation like a stock market downtrend, bonds and commodities such as gold rise against those declines.
- Optimised Risk-Adjusted Returns: Diversification aims to produce maximum returns from a given risk level. This can be achieved by dispersing investments between low-risk and high-risk assets, allowing for growth without the possibility of losses.
- Protection from Market Shocks: An investor cannot predict when his industry or region will run into trouble. A well-diversified portfolio protects against such shocks, which could be sector-specific in nature or due to a political crisis.
- Emotional Stability: The volatility of the periods is less likely to be caused by diversified portfolio investors since their losses are usually cushioned. This emotional stability makes the likelihood of making irrational decisions, such as selling at the wrong time, unlikely.
- Long-term wealth building: Diversification ensures consistent growth by minimising huge losses and creating the potential for compounding returns. It is thus an essential strategy for securing long-term financial goals such as retirement planning.
Examples of Portfolio Diversification
Theoretical Portfolio Allocation
Consider the following simple diversified portfolio allocation:
| Asset Class | Allocation Percentage |
| US Stocks | 40% |
| International Stocks | 20% |
| Bonds | 20% |
| Real Estate | 10% |
| Cash Equivalents | 10% |
In this case, the investor owns a balance of growth, stability, and liquidity from various assets.
Real-World Examples:
ETF Diversification
ETFs are a great method for achieving portfolio diversification without any high costs. The advantage of ETFs is that investors can invest in multiple asset classes, sectors, and geographies by simply making one investment. For example, let’s imagine an investor who creates an ETF-diversified portfolio.
- SPDR S&P 500 ETF Trust (SPY): This investment tracks the performance of the S&P 500 Index, which comprises 500 of the largest publicly traded companies in the United States. Thus, it provides broad exposure to the US stock market by including technology, healthcare, and finance sectors. By investing in SPY, the investor captures the growth potential of leading US companies while diversifying across industries.
- iShares MSCI Emerging Markets ETF (EEM): This ETF provides exposure to growing markets such as China, India, and Brazil. These markets are inclined to have higher growth rates than developed economies but come with higher risks. Adding EEM to the portfolio will provide international diversification and the ability to take advantage of the economic growth of developing countries.
- iShares Core US Aggregate Bond ETF (AGG): Bonds should be the heart of a diversified portfolio as they provide a stable and income-generating component. AGG tracks a wide range of US investment-grade bonds—government, corporate, and mortgage-backed, among others—to offer investors a safe haven and diversification while acting as a counterweight to riskier equities.
This will give the investor a diversified portfolio containing exposure to US equities, international markets, and fixed-income securities. It will help manage risks by providing growth opportunities, and the mix is a great practical example of diversification in action.
Frequently Asked Questions
While diversification is an effective strategy, it is without its disadvantages:
- Diminished Returns: It dilutes returns by including too many low-performing assets.
- Complexity: A diversified portfolio needs continuous monitoring and rebalancing.
- Costs: Transaction costs, as well as management charges, can be significant.
Long-term diversification relies on strategic asset allocation, which is stable over time. For instance, a retirement portfolio with a mix of stocks and bonds designed to grow steadily over decades.
Short-term diversification involves tactical changes according to present market conditions. For example, it involves changing assets to cash or bonds during a decline for immediate protection.
Rebalancing keeps your portfolio current with your targeted asset mix. Steps involved
- Examining your portfolio on an annual or semi-annual basis.
- Identifying those asset classes that have risen or fallen more than is consistent with your initial strategy
- Sell those performing asset classes and return funds to underperforming classes to rebalance the portfolio.
Mutual funds and ETFs are great instruments for diversification:
- Mutual Funds: Managed portfolios with access to various asset classes, industries, and geographies.
- ETFs: Low-cost and liquid funds that track a particular index or sector, ideal for the new investor.
- Example: The Vanguard Total Stock Market ETF (VTI) gives access to the US stock market, while the SPDR Gold Shares (GLD) offers diversification into commodities like gold.
Fixed income diversification is the process of spreading investments across various types of bonds, such as:
- Government Bonds: Low-risk options like US Treasury bonds or Singapore Government Securities (SGS).
- Corporate Bonds: Issued by companies, offering higher returns but greater risk.
- Municipal Bonds: These bonds are issued by local governments and usually carry tax benefits.
- Example: Long-term US Treasury bonds and short-term corporate bonds provide stability and growth.
Related Terms
- Gamma Scalping
- Free-Float Methodology
- Flight to Quality
- Equity Carve-Outs
- Ladder Strategy
- Event-Driven Strategy
- Dividend Capture Strategy
- Credit Default Swap (CDS)
- Company Fundamentals
- Buy And Hold Strategy
- Withdrawal Plan
- Basis Risk
- Barbell Strategy
- Risk budgeting
- Trading Strategy
- Gamma Scalping
- Free-Float Methodology
- Flight to Quality
- Equity Carve-Outs
- Ladder Strategy
- Event-Driven Strategy
- Dividend Capture Strategy
- Credit Default Swap (CDS)
- Company Fundamentals
- Buy And Hold Strategy
- Withdrawal Plan
- Basis Risk
- Barbell Strategy
- Risk budgeting
- Trading Strategy
- High-Yield Investment Programs
- Risk Appetite
- Closing Transaction
- Replication Strategy
- Correlation Coefficient
- Currency hedge
- Automatic Investment Plan
- Automatic Reinvestment
- Core-Satellite Strategy
- Overlay Strategy
- Long/Short Strategy
- Strategic Asset Allocation
- Tactical Asset Allocation
- Gearing
- Dividend stripping
- Resting Order
- Buy to opening
- Buy to Close
- Yield Pickup
- Contrarian Strategy
- Interpolation
- Intrapreneur
- Hyperledger composer
- Horizontal Integration
- Queueing Theory
- Homestead exemption
- The barbell strategy
- Retirement Planning
- Credit spreads
- Stress test
- Accrual accounting
- Growth options
- Growth Plan
- Advance Decline Line
- Accumulation Distribution Line
- Box Spread
- Charting
- Advance refunding
- Accelerated depreciation
- Amortisation
- Accrual strategy
- Hedged Tender
- Value investing
- Long-term investment strategy
Most Popular Terms
Other Terms
- Bond Convexity
- Compound Yield
- Brokerage Account
- Discretionary Accounts
- Industry Groups
- Growth Rate
- Green Bond Principles
- Funding Ratio
- Foreign Direct Investment (FDI)
- Floating Dividend Rate
- Real Return
- Protective Put
- Perpetual Bond
- Option Adjusted Spread (OAS)
- Non-Diversifiable Risk
- Merger Arbitrage
- Liability-Driven Investment (LDI)
- Income Bonds
- Guaranteed Investment Contract (GIC)
- Flash Crash
- Cost of Equity
- Cost Basis
- Deferred Annuity
- Cash-on-Cash Return
- Earning Surprise
- Capital Adequacy Ratio (CAR)
- Bubble
- Beta Risk
- Bear Spread
- Asset Play
- Accrued Market Discount
- Junk Status
- Intrinsic Value of Stock
- Interest-Only Bonds (IO)
- Interest Coverage Ratio
- Inflation Hedge
- Industry Groups
- Incremental Yield
- Industrial Bonds
- Income Statement
- Holding Period Return
- Historical Volatility (HV)
- Hedge Effectiveness
- Flat Yield Curve
- Fallen Angel
- Exotic Options
- Execution Risk
- Exchange-Traded Notes
- Eurodollar Bonds
- Enhanced Index Fund
Know More about
Tools/Educational Resources
Markets Offered by POEMS
Read the Latest Market Journal
Beyond The Usual Markets: Discover Kazakhstan
A Closer Look At Kazakhstan As Kazakhstan gains popularity as a travel destination across Central Asia, attention is slowly shifting from tourism to opportunity. What many don’t realise is that the same country attracting visitors today is also offering high-yield, under-owned investment opportunities that global markets have yet to fully price in. Most investors today are crowded into the same trades — US tech, India growth, or China recovery. But some of the most compelling opportunities are often found where few are looking. Kazakhstan is one of those markets. It is not a headline market. It is not widely covered. But that’s exactly where its opportunity lies. This article breaks down why Kazakhstan deserves a place in your portfolio — and how you can actually invest in it. Why Kazakhstan, And Why Now? Kazakhstan is the world's ninth-largest country by area, the world's largest uranium producer, and a top-ten oil exporter. Its stock exchange, Kazakhstan Stock Exchange (KASE), has quietly delivered 40% returns over the past 12 months, beating most developed and emerging markets. Yet non-residents account for just 8.3% of trading volume. The institutional wave has not arrived yet. We believe this represents a genuine early-mover window. The Astana International Financial Centre (AIFC), modelled on Dubai's DIFC and backed by a 2026–2028 strategy to attract sovereign wealth funds and global pension capital, has already channelled $21.5 billion in structured investment since inception, including $7.2 billion in 2025 alone. The infrastructure is being built to handle institutional money at scale. The question is whether your portfolio is positioned before that happens. Four Reasons This Market Stands Out The Tax Advantage: Plain And Simple Kazakhstan's tax regime for foreign investors in listed equities is one of the most favourable we have seen in any comparable market. Here is what matters most when investing through our platform. Tax-related information provided is for general guidance only. Please consult your tax advisor for confirmation and clarification. Five Stocks To Start With These five names represent the most liquid, transparent, and well-covered companies on KASE across five distinct sectors. Each was chosen for accessibility and suitability for investors new to the market. Risks To Keep In Mind Trade Kazakhstan With POEMS Kazakhstan-listed shares are now available for online trading through POEMS. Trading Hours (SGT) Pre-Opening Session 2:20PM – 2:30PM Main Continuous Session 2:30PM – 8:30PM For more information, visit POEMS or contact our Global Markets Desk at talktoglobalmarkets@phillip.com.sg. Make Kazakhstan Part Of Your Global Market View Explore Kazakhstan on POEMS and discover opportunities across KASE. Trade Open An Account Now! DisclaimerDisclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Keppel DC REIT Strengthens Japan Expansion with Major Tokyo Data Centre Acquisition
Brief Overview Keppel DC REIT (KDCREIT) has agreed to jointly acquire a 90% effective interest in two hyperscale data centres in Greater Tokyo for JPY190 billion (S$1,549 million). The acquisition is expected to be 2.6% accretive to FY25 pro-forma distribution per unit (DPU) and will significantly deepen the REIT's Japan presence. The properties offer contractual rent escalation of 2.8% per annum and are under-rented by at least 30%. Investment Positives The acquisition presents multiple compelling growth drivers for long-term income expansion. Tokyo Data Centre 4 and 5 are freehold colocation facilities that are 100% occupied by four investment-grade clients, providing strong tenant quality and full occupancy rates. The properties offer a balanced risk-return profile with a blended weighted average lease expiry (WALE) of 8.3 years, combining reversion opportunities with long-term income visibility. The deal provides substantial embedded rental upside potential, with in-place rents under-rented by at least 30% and contracted average annual rent escalation of approximately 2.8%. More than 5% of rents are due for renewal by 2029, creating near-term reversion opportunities. The acquisition was secured at a 2.1% discount to the properties' valuation of JPY194 billion, representing attractive pricing. Strategically, the acquisition strengthens KDCREIT's position in one of Asia Pacific's most attractive data centre markets. Japan's contribution to portfolio rental income will increase significantly from approximately 9% as at 30 June 2026 to approximately 23% post-acquisition. The properties are located in Inzai City, one of Japan's most established hyperscale data centre clusters. Japan's market fundamentals support long-term growth prospects, underpinned by rising cloud adoption, AI-related deployments and digital transformation. Structural supply constraints, including power constraints, construction bottlenecks and land scarcity, should further enhance the market's growth potential. Investment Negatives The acquisition will increase aggregate leverage from 34% to 38%, representing a meaningful increase in the REIT's debt levels. The financing structure requires a substantial private placement to raise at least S$600 million, which will increase the unit base by approximately 12%, creating dilution for existing unitholders. The acquisition is scheduled to complete in 4Q26, meaning investors will need to wait for the benefits to materialise. Outlook The transaction combines immediate DPU accretion with multiple avenues for long-term income growth. Japan's favourable demand-supply dynamics should support continued growth, while the portfolio's asset under management is expected to grow to S$7.6 billion from S$6.3 billion. Recommendation & Target Price Phillip Securities Research maintains an ACCUMULATE recommendation with an unchanged target price of S$2.46. The analysts have yet to update their financials for the acquisition and private placement but remain positive on the deal's strategic value and accretive nature. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Geo Energy Resources Ltd – De-risked, ready to rumble
Brief Overview Geo Energy Resources delivered 1H26 results within expectations, with revenue and net profit representing 36% and 37% respectively of full-year forecasts. The company's US$190 million integrated infrastructure project has been completed and operational since July, whilst production declined 42% year-on-year to 3.8 million tonnes as operations shift to the new infrastructure. The sales target for FY26 remains unchanged at 11.5-12.5 million tonnes. Investment Positives The completion and operational status of Geo's integrated infrastructure represents a significant milestone for the company. The 92-kilometre hauling road and jetty facility, held through 69.9% subsidiary Marga Bara Jaya (MBJ), has a substantial capacity of 25 million tonnes and went live operationally in July. This development is expected to drive meaningful production improvements, with Geo anticipated to transport 4 million tonnes of coal through MBJ in 2H26, rising to 11 million tonnes in FY27. The infrastructure's excess capacity creates additional revenue streams through toll and jetty fees supported by multi-year contracts. Production capabilities are set to enhance further as 2x70MT trucks arrive in September to replace the current 40MT fleet, supporting operational ramp-up. Looking ahead to FY27, analysts forecast production to surge 40% to 17 million tonnes whilst cash costs are expected to decline. The coal price environment also provides tailwinds, with prices up 53% year-on-year in 3Q26. Gross margins improved to 18.9% from 15.6% previously, supported by a 16.5% rise in average selling prices to US$529 per tonne. Investment Negatives The primary concern centres on the significant production decline in 1H26, where output fell 42% year-on-year to 3.8 million tonnes. This reduction stems from deliberate delays in TRA production ramp-up as the company transitions coal transportation from the existing Atlas road to its proprietary MBJ infrastructure. Additionally, TBR pit boundary expansion due to high wall pushback contributed to operational disruptions, with TBR production dropping 51% to 2 million tonnes. Cash costs increased 12.5% to US$40.6 per tonne, attributed to higher fuel prices, which pressured operational margins during the transition period. Outlook With the integrated infrastructure now operational, Geo's earnings visibility has been substantially de-risked. FY27 represents a milestone year with forecast production growth of 40% and declining cash costs, supported by infrastructure fee income from multi-year contracts and favourable coal price trends. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with an unchanged DCF target price of S$0.75. The FY26 earnings forecast remains unchanged following the results. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
NVIDIA Corporation – Strong Growth Driven by AI Infrastructure Demand
Brief Overview NVIDIA delivered 2Q27 results within expectations, with data centre revenue surging 117% year-on-year to US$89bn. The company guided FY28e revenue growth of about 70% year-on-year, though this is constrained by supply factors. Phillip Securities Research maintains a BUY rating with a raised target price of US$300. Investment Positives Hyperscale revenue showed significant acceleration in 2Q27, growing 102% year-on-year to US$48.7bn, compared to 93% growth in 1Q27. This acceleration was driven by hyperscalers increasing capital expenditure spending on GPU capacity, particularly for Blackwell Ultra. The top four hyperscalers - Google, Amazon, Microsoft, and Meta - increased their 2026e capital expenditure guidance by 5% this quarter to US$748bn, representing 97% year-on-year growth. NVIDIA expects their total capital expenditure to reach US$1.3tn in 2027e, reflecting 74% year-on-year growth. Amazon is deploying an additional 2 million of NVIDIA's GPUs until 2Q29e, whilst Microsoft announced plans to modernise its infrastructure with NVIDIA's Vera Rubin, which commenced shipments in August. The AI Clouds, Industrial & Enterprise (ACIE) segment recorded the fastest growth, with 2Q27 revenue spiking 138% year-on-year, overtaking hyperscale growth rates. This growth was supported by significant contract wins, including AI startups Reflection and Cohere signing multi-year contracts worth US$1bn or more with Nebius for AI workloads running on NVIDIA-powered infrastructure. Sovereign AI revenue more than tripled year-on-year, with substantial partnerships announced. NVIDIA partnered with Noetra, Japan's national AI company, to deploy 13,750 Vera CPUs and 27,500 Rubin GPUs delivering 140MW of AI compute for physical AI. South Korea committed to invest at least US$3bn for NVIDIA and Hyundai to deploy 50,000 Blackwell GPUs for AI model training and deployment. Investment Negatives The report indicates that rising memory costs present a headwind to NVIDIA's margins, which prompted the analyst to raise the weighted average cost of capital to 8.4% from 7.9%. Supply constraints including land, power, shell, and cooling are limiting NVIDIA's revenue growth potential. Without these constraints, demand could grow more than 100% in FY28e, compared to the guided 70% growth. Outlook Global semiconductor spending surged 108% year-on-year in 1H2026 to US$675bn, driven by hyperscaler, enterprise, and sovereign nations' AI buildout. The analyst raised FY27e revenue and PATMI forecasts by 11% due to stronger expected growth from the ACIE segment and rapid Vera Rubin ramp in 2H27e. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with a raised target price of US$300, increased from the previous US$285. NVIDIA trades at a FY27e price-to-earnings ratio of 24x, representing a 32% discount to peers' average of 35x. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Salesforce Inc – The End of the SaaSpocalypse
Brief Overview Salesforce delivered mixed second quarter results with revenue meeting expectations but profit after tax and minority interest (PATMI) lagging due to higher research and development and sales & marketing spending. The company is positioning itself as the enterprise AI data layer through Headless and Claudeforce initiatives, extending CRM data into platforms like Claude, Slack and Teams. Management anticipates second half growth driven by premium AI products and usage-based monetisation, with significant growth potential as only 5% of users currently use higher-tier editions. Investment Positives The core Sales and Service Cloud divisions continue to demonstrate resilience as revenue anchors. Revenue increased 11% year-on-year to US$11.3 billion, maintaining consistent growth momentum from the previous quarter's 10% increase. The sales division faces minimal AI disruption since monetisation primarily occurs through upselling existing Salesforce offerings. Customer retention metrics remain exceptionally strong with attrition near record lows, whilst Sales, Service and Slack all delivered seat growth. Existing customers are actively upgrading through premium AI-enabled bundles, particularly Agentforce 1 Edition for premium Sales and Service Cloud. Agentforce application bookings have also more than doubled quarter-on-quarter, whilst premium Slack upgrades tripled following Slackbot's March 2026 launch. The agentic AI momentum continues to accelerate significantly. Agentforce annual recurring revenue exceeded US$1.5 billion, representing approximately 3.3% of FY27 revenue guidance midpoint and marking growth of more than 240% year-on-year. The consumption-based pricing model encourages rapid customer adoption, with Agentforce bookings doubling quarter-on-quarter. Notably, 50% of new bookings came from existing customers purchasing additional credits after initial deployment. Growth products including Agentforce, Headless and Data 360 collectively reached nearly US$3.9 billion in annual recurring revenue. Salesforce benefits from owning crucial customer data, workflows, permissions and governance layers that support data quality, whilst customers increasingly prefer AI embedded within existing software rather than managing complex internal AI systems. Investment Negatives The report identifies higher research and development, marketing and sales expenses as factors contributing to lower-than-expected earnings performance. These increased operational costs resulted in PATMI lagging behind revenue performance during the quarter. Outlook Management expects second half growth to be driven by premium AI products including Agentforce, Slackbot and Claudeforce, alongside usage-based monetisation and customer upgrades. The growth runway remains substantial given that only 5% of users currently utilise higher-tier editions. Recommendation & Target Price Phillip Securities Research maintains a NEUTRAL recommendation whilst raising the DCF target price to US$243 from the previous US$166. The analysts increased their terminal growth rate from 3% to 5.5%, reflecting improved market confidence in Salesforce's core CRM business, the Anthropic Claudeforce partnership, and stronger software sector sentiment as enterprise AI monetisation gains traction. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Thomson Medical Group Ltd Shows Turnaround Progress Despite Volume Challenges
Brief Overview Thomson Medical Group delivered FY26 results largely in line with expectations, with revenue and EBITDA meeting 97% and 98% of forecasts respectively. The company experienced earnings recovery across all three operating countries - Singapore, Malaysia, and Vietnam - with EBITDA expanding 21% year-on-year in the second half to S$43.6mn. Growing revenue intensity has driven earnings improvements, though currency headwinds affected results. Investment Positives The primary positive driver for Thomson Medical has been the significant growth in average bill size across all three operating markets. Singapore recorded the largest increase in average bill size at 421.8%, driven by a combination of increased case complexity and a higher product mix as procedures were shifted to outpatient day surgery. Malaysia also benefited from improved revenue intensity, with average bill size growing 111.9%. This improvement was supported by oncology and gastroenterology cases, alongside the return of some insurance payers. The Malaysian operations saw EBITDA expand 34.6% as the business rebuilds its insurance relationships. Vietnam demonstrated strong operational momentum with inpatient volumes increasing 46.5% and average bill size growing 2.1%. The Vietnamese operations benefited from higher volumes including robotic surgery procedures and increased capacity, resulting in EBITDA growth of 52.4%. The group's strategic pivot away from Singapore's historical reliance on obstetrics and gynaecology cases is showing results, with the addition of more orthopaedics, ENT and general surgery procedures improving the revenue mix. Investment Negatives The key challenge facing Thomson Medical is declining volumes across the group. Total inpatient volumes fell 7.8% year-on-year to 39,000 patients in FY26. Singapore experienced a 9% decline in inpatient volumes, primarily due to lower delivery cases in obstetrics. Malaysia recorded an 11.5% drop in inpatient volumes, which the analyst attributes to the absence of insurance payers. Finance costs continue to weigh on earnings despite a 16.5% reduction due to lower interest rates. The company also recorded a S$15.2mn goodwill impairment due to a higher discount rate assumption. Outlook The analyst views Thomson Medical as successfully executing its operational turnaround strategy. The company is effectively diversifying Singapore away from obstetrics cases whilst Malaysia rebuilds its insurance partnerships with foreign patients and oncology leading increased revenue intensity. However, finance costs remain a burden on earnings performance. Recommendation & Target Price Phillip Securities Research has upgraded Thomson Medical to BUY due to recent share price performance. The target price remains unchanged at S$0.071 using a sum-of-the-parts valuation approach. The analyst maintained FY27e earnings forecasts while rolling over valuations to FY27e earnings. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
iX Biopharma Ltd – Galloping Closer with Partners
Brief Overview iX Biopharma's FY26 results fell below expectations, with revenue and net loss at 72% and 170% of forecast respectively. The US$40.9mn Wafermine Programme from the US Department of Defense has commenced, with the company recognising S$1.2mn as development services. The analyst expects revenue to triple in FY27e, driven by compounding pharmacy operations, Wafermine sales, and development services. Investment Positives The primary investment driver centres on the Wafermine development programme, which is just beginning to gain momentum. Since receiving the Department of Defense award in February, approximately four months of development work have been completed. The analyst expects revenue to climb significantly as more development work for Emergency Use Authorisation (EUA) and Phase 3 trials is undertaken. The company has secured substantial funding through the US$40.9mn Wafermine Programme, which will finance both Phase 3 and EUA development activities. This programme has already started generating revenue, with S$1.2mn recognised as development services in the current period. Revenue diversification is expected to strengthen the business model, with three key growth drivers anticipated for FY27e: the compounding pharmacy operations with partner Orion Speciality, Wafermine sales, and continued development services revenue. The company also benefited from currency movements, with other gains of S$2.1mn resulting from the strengthening of the Australian dollar against the Singapore dollar. Investment Negatives Operating expenses were significantly higher than anticipated, presenting a key challenge for the company. The main contributors were a S$2.08mn share performance plan (non-cash) and S$1mn in one-off professional fees related to securing the Department of Defense funding contract. However, excluding these items, operating expenses remained largely stable. General and administrative expenses increased by 58%, primarily due to the S$2mn performance share plan. Research and development costs also rose by 52% to S$2.5mn. The transfer of equipment from Australia to the United States resulted in lower medicinal cannabis sales, with approximately S$3mn in lost revenue. Cannabis sales specifically declined by 46% to S$3.5mn, contributing to the overall revenue shortfall. Outlook The analyst has incorporated higher upfront costs from US wholesale compounding pharmacy operations and increased performance shares into updated forecasts. Key milestones ahead include the Wafermine EUA submission in 4Q26, EUA approval in 1Q27, EUA production in 2Q27, and Phase 3 trials approval in 2Q27. The US production line is expected to commence in 1Q27, with three additional lines starting in 2Q27. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with an unchanged DCF SOTP target price of S$1.00. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
CapitaLand Investment Limited – Event-Driven Fees Supported a Strong 1H26
Brief Overview CapitaLand Investment Limited (CLI) reported 1H26 revenue 2% lower year-on-year while PATMI rose 14% YoY, in line with expectations and forming 44% and 52% of Phillip Securities Research's FY26e forecasts respectively. PATMI growth was driven by stronger event-driven fees from Listed and Private Funds Management, as well as lower interest costs of 7% YoY. In addition, S$7-9 billion of embedded value has been identified in non-core investments across legacy funds, balance sheet assets, and non-strategic holdings, providing scope for capital recycling and value realisation. Funds under management grew to S$128 billion from S$125 billion in FY25, supported by S$3.7 billion raised in 1H26. Investment Positives Significant fee revenue growth in Listed and Private Funds Management represents the key positive. Listed Funds Management revenue grew 45% YoY, driven by a sharp increase in event-driven fees from S$4 million in 1H25 to S$66 million in 1H26, supported by over S$10 billion in transactions. Private Funds Management fee revenue grew 59% YoY, driven by the Wingate acquisition and higher operating activity across the platform. Operating PATMI of S$293 million rose 13% YoY, while revenue from the Fund and REIT Management Business (FRB) grew 20% YoY, partially offsetting a 24% decline in Real Estate Investment Business (REIB) revenue due to the deconsolidation of Synergy and divestments. Investment Negatives Net gearing edged up from 0.41x to 0.45x on a quarter-on-quarter basis, leaving S$6 billion of debt headroom before reaching CLI's 0.9x internal threshold. Nevertheless, the cost of debt continued to decline, falling by 0.1 percentage point QoQ to 3.5%, down from 3.9% in FY25. The cost of debt is expected to remain at current levels in FY26e. Outlook CLI remains focused on scaling its fund management business through high-conviction themes such as lodging, logistics, self-storage, private credit, and data centres, particularly in resilient markets such as Singapore, to attract institutional capital and drive fee income growth. It has identified S$7-9 billion of embedded value in non-core legacy funds and balance sheet assets for potential recycling, with around two-thirds located in China and 30-40% in private funds. While CLI intends to divest non-core China investments, it remains committed to growing its China fund management franchise, as evidenced by the CNY3.15 billion China Commercial Private REIT listing on 11 August and a second C-REIT listing targeted for 2H26. The analyst expects fund management revenue to continue growing in FY26, although transaction-related activity may moderate from the strong levels recorded in 1H26. Recommendation & Target Price Phillip Securities Research maintains a BUY recommendation with an unchanged sum-of-the-parts target price of S$3.69. There are no changes to forecasts. The analyst believes CLI's ability to monetise its China assets at reasonable valuations rather than distressed prices, and redeploy the proceeds into core growth opportunities, could unlock embedded value and provide a catalyst for a re-rating of the stock. Frequently Asked Questions [market_journal_faq] This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
